Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC

Abstract Background Hepatocellular carcinoma (HCC) ranks sixth amongst all cancers and is the 2nd top cause of mortality attributable to cancer. Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-free regimens in chronic people with HCV after the suc...

書目詳細資料
發表在:	Egyptian Liver Journal
Main Authors:	Amr Maged Mahmoud Rasheed, Maissa E. L. Raziky, Mohammad El Sayed, Mai Mehrez, Gamal Esmat
格式:	Article
語言:	英语
出版:	SpringerOpen 2025-02-01
主題:	HCV HCC Cirrhosis DAAs SVR RFA
在線閱讀:	https://doi.org/10.1186/s43066-025-00406-2

相似書籍

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
由: Chung-Feng Huang, et al.
出版: (2024-10-01)

Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India
由: Astha, et al.
出版: (2025-03-01)

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis
由: Alessia Siribelli, et al.
出版: (2025-06-01)

Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients
由: Ghada M. Salum, et al.
出版: (2020-09-01)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
由: Reham M. Dawood, et al.
出版: (2022-08-01)

Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: A meta-analysis
由: Tian Zeng, et al.
出版: (2023-01-01)

Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice
由: Ming-Ling Chang, et al.
出版: (2021-08-01)

Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV
由: Zuzana Macek Jilkova, et al.
出版: (2021-12-01)

Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model
由: Ching-Chu Lo, et al.
出版: (2023-08-01)

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
由: Chen-Ta Chi, et al.
出版: (2021-06-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
由: Devis Pascut, et al.
出版: (2020-06-01)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
由: Vincenzo Scaglione, et al.
出版: (2020-02-01)

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C
由: Xiaobo Zhu, et al.
出版: (2024-10-01)

Main insights of genome wide association studies into HCV-related HCC
由: Inas Maged Moaz, et al.
出版: (2020-02-01)

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
由: Chung-Feng Huang, et al.
出版: (2025-04-01)

Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
由: Masahito Nakano, et al.
出版: (2019-05-01)

The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma
由: Yuelong Chai, et al.
出版: (2019-05-01)

Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents
由: Ashraf Elbahrawy, et al.
出版: (2023-10-01)

Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
由: Jowana Saba, et al.
出版: (2018-02-01)

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study
由: Filomena Morisco, et al.
出版: (2024-09-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
由: Luca Rinaldi, et al.
出版: (2019-08-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
由: Nawfal R Hussein
出版: (2017-01-01)

HCV eradication in people living with HIV: the final countdown?
由: A. De Vito, et al.
出版: (2021-02-01)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
由: Nahed Mohammed Hawsawi, et al.
出版: (2023-01-01)

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR
由: Al-Shazly Gaber Mohamed Galal, et al.
出版: (2023-08-01)

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series
由: Fabian Patauner, et al.
出版: (2022-07-01)

Trends in long‐term outcomes of patients with HCV‐associated hepatocellular carcinoma after hepatectomy: A comparison before and after introduction of direct‐acting antivirus therapy
由: Fumiaki Munekage, et al.
出版: (2024-01-01)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
由: Mohammad Asrar Izhari
出版: (2023-09-01)

B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels
由: Ali Nada, et al.
出版: (2021-07-01)

Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
由: Mariantonietta Di Stefano, et al.
出版: (2021-09-01)

The Role of RASs /RVs in the Current Management of HCV
由: Konstantinos Malandris, et al.
出版: (2021-10-01)

Interaction between HOTTIP, H19, and HOTAIR long noncoding RNAs and miRNA-152 in cases of HCC caused by HCV infection
由: Rady E. El-Araby, et al.
出版: (2024-05-01)

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
由: Chung-Feng Huang, et al.
出版: (2024-07-01)

Performance of Elecsys<sup>®</sup> HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection
由: Prooksa Ananchuensook, et al.
出版: (2024-09-01)

Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication
由: Filippo Biagi, et al.
出版: (2023-10-01)

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
由: Reem El-Shenawy, et al.
出版: (2024-11-01)

Cardiac toxicity associated with HCV direct antiviral agents
由: Claudio Ucciferri, et al.
出版: (2018-10-01)

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
由: Andri Sanityoso Sulaiman, et al.
出版: (2023-12-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
由: Inas E L-Khedr Mohamed, et al.
出版: (2021-04-01)

Evaluation of alcohol use behavior among patients cured through HCV elimination program in Georgia
由: Maia Butsashvili, et al.
出版: (2024-06-01)